SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001725160-21-000099
Filing Date
2021-04-23
Accepted
2021-04-23 16:05:13
Documents
7
Period of Report
2021-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A proxystatement-2021.htm DEF 14A 648912
2 alexispinto-signaturexcropa.jpg GRAPHIC 45847
3 image_01.jpg GRAPHIC 3977
4 image_31.jpg GRAPHIC 23775
5 tonysun-signaturexcropped1.jpg GRAPHIC 28212
6 zentalispharmaceuticalsinc.jpg GRAPHIC 237030
7 zentalispharmaceuticalsinca.jpg GRAPHIC 242211
  Complete submission text file 0001725160-21-000099.txt   1440217
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39263 | Film No.: 21849718
SIC: 2834 Pharmaceutical Preparations